IGC Pharma Inc (IGC)
IGC Pharma Inc is a clinical-stage pharmaceutical company listed on the NYSE under the symbol IGC. The company is focused on developing therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with an emphasis on Alzheimer’s disease in the United States and Colombia. Its lead program, IGC-AD1, is in Phase II clinical testing for agitation associated with dementia due to Alzheimer’s disease. The pipeline also includes pre-clinical candidates TGR-63 and IGC-M3 for Alzheimer’s disease, along with MINT-AD, an AI-based assistant designed for healthcare providers. Founded in 2005 and headquartered in Potomac, Maryland, the company was previously known as India Globalization Capital, Inc. until its name change in March 2023.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-IGC
|
$0.26
|
-4.4% Downside
|
Fair
|
$4.25 1,481.7% Upside
|
—
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
November 18, 2026
|
-4.1x
|
3.3x
|
24.1x
|
26.814 M
|
27.355 M
|
0.5%
|
86.0%
|
-30.8
|
—
|
87.3%
|
